Biogen entered a major collaboration with Stoke Therapeutics, paying $165M to co-develop and commercialize zorevunersen for Dravet syndrome. This large investment indicates a high-priority strategic initiative requiring significant resources for global clinical trials, regulatory submissions, and commercial launch planning outside of North America.
Filing excerpt
In February 2025 we entered into a collaboration and license agreement with Stoke to co-develop and commercialize zorevunersen, an investigational ASO that targets the SCN1A gene for the potential treatment of Dravet syndrome...
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
Vendors
Regions named
Vendors named
sec-10kjointVentureGet every 10-K signal for Biogen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/be9b7e31-f89a-46d2-b978-e14950d86fa6 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.
{
"signal_id": "be9b7e31-f89a-46d2-b978-e14950d86fa6",
"signal_type": "sec-10k",
"signal_subtype": "jointVenture",
"detected_at": "2026-02-10T07:50:47.777+00:00",
"company": {
"name": "Biogen",
"domain": "biogen.com"
},
"data": {
"detail": "Biogen entered a major collaboration with Stoke Therapeutics, paying $165M to co-develop and commercialize zorevunersen for Dravet syndrome. This large investment indicates a high-priority strategic initiative requiring significant resources for global clinical trials, regulatory submissions, and commercial launch planning outside of North America.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Upfront payment to Stoke Therapeutics for collaboration.",
"dollar_millions": 165
},
"summary": "Biogen paid Stoke Therapeutics $165M upfront to co-develop and commercialize a rare disease drug",
"excerpts": "In February 2025 we entered into a collaboration and license agreement with Stoke to co-develop and commercialize zorevunersen, an investigational ASO that targets the SCN1A gene for the potential treatment of Dravet syndrome...",
"relevance": 0.85,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm",
"filing_date": "2026-02-06",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "New entity needs",
"signal_category": "strategic",
"regions_mentioned": [
"U.S.",
"Canada",
"Mexico",
"rest of the world"
],
"vendors_mentioned": [
"Stoke Therapeutics, Inc."
],
"technologies_mentioned": [
"ASO"
]
}
}
curl https://signals.autobound.ai/v1/signals/be9b7e31-f89a-46d2-b978-e14950d86fa6 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.